Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M. Llovet, Peiguo Cao, Shukui Qin et al.|The Lancet Oncology|2023Cited by 436
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 studyFeng Bi, Jiayuan Wu, Shukui Qin et al.|European journal of medical research|2025Cited by 1